{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:15:34Z","timestamp":1790972134055,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jhep.2021.01.047","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T03:41:10Z","timestamp":1613014870000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"75","author":[{"given":"Stephen A.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa R.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Shim-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandee","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.01.047_bib1","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2021.01.047_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.047_bib3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.047_bib4","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicenter, randomized, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib5","first-page":"1479A","article-title":"Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR part C interim results","volume":"70","author":"Lucas","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.047_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with non-cirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib7","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(20)30570-5","article-title":"Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing","volume":"73","author":"Aspinall","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib8","first-page":"1049A","article-title":"MET409, a potent, novel, non-bile acid FXR agonist, in rodents and cynomolgus monkeys","volume":"68","author":"Wagner","year":"2017","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib9","first-page":"1006A","article-title":"MET409, a potent, non-bile acid sustained FXR agonist, shows rapid disease reversal in a diet-induced obese mouse model of biopsy-confirmed NASH","volume":"69","author":"Wagner","year":"2018","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib10","first-page":"E789","article-title":"MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects","volume":"70","author":"Chen","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib11","first-page":"1257A","article-title":"MET409, a sustained FXR agonist, decreased hepatic fat and improved liver function without raising LDL-C after 28 days in NASH patients","volume":"70","author":"Harrison","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.047_bib12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A\u00a0chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"4","author":"Downes","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2021.01.047_bib13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2009.08.001","article-title":"Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders","volume":"30","author":"Fiorucci","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jhep.2021.01.047_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.01.047_bib15","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2021.01.047_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/mol.105.012104","article-title":"The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)\/9-cis retinoid X receptor and regulates transcription of FXR responsive genes","volume":"68","author":"Rizzo","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2021.01.047_bib17","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-019-10853-2","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"10","author":"Merk","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2021.01.047_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","article-title":"Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease","volume":"60","author":"Banerjee","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.047_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic\u00a0resonance vs. transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis\u00a0of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.047_bib20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mrm.25054","article-title":"Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging","volume":"72","author":"Zhong","year":"2014","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.jhep.2021.01.047_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2214\/AJR.14.12457","article-title":"Quantification of hepatic steatosis with a multistep adaptive fitting MRI approach: prospective validation against MR spectroscopy","volume":"204","author":"Bashir","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2021.01.047_bib22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.047_bib23","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib24","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0168-8278(20)30656-5","article-title":"Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial","volume":"73","author":"Loomba","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.047_bib25","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2021204325","article-title":"Week 4 liver fat reduction on MRI as an early predictor of treatment response in participants with NASH","author":"Jiang","year":"2021","journal-title":"Radiology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2021.01.047_bib26","first-page":"169A","article-title":"Effects of resmetirom (MGL-3196) on hepatic fat, lipids, liver enzymes and markers of liver fibrosis in an open-label 36-week extension study in NASH patients","volume":"70","author":"Harrison","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.047_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis inpatients with type 2 diabetes in the US","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2021.01.047_bib28","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/jgh.14734","article-title":"Type 2 diabetes mellitus: a risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease","volume":"34","author":"Tada","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.047_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.31265","article-title":"FXR agonists as therapy for liver disease","volume":"72","author":"Hoofnagle","year":"2020","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:42:07Z","timestamp":1759174927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0168827821000994"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.047","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}